Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.
about
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy, safety, Low density ...... post-commercialization study.
@en
Efficacy, safety, Low density ...... post-commercialization study.
@nl
type
label
Efficacy, safety, Low density ...... post-commercialization study.
@en
Efficacy, safety, Low density ...... post-commercialization study.
@nl
prefLabel
Efficacy, safety, Low density ...... post-commercialization study.
@en
Efficacy, safety, Low density ...... post-commercialization study.
@nl
P2093
P2860
P1476
Efficacy, safety, Low density ...... post-commercialization study.
@en
P2093
Charles J Glueck
Chris Mahida
Ilana Schlam
Matan Rothschild
Naila Goldenberg
Parth Shah
P2860
P2888
P356
10.1186/S12944-017-0416-7
P577
2017-01-23T00:00:00Z
P6179
1074191712